<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03121053</url>
  </required_header>
  <id_info>
    <org_study_id>PANTER_V1.1</org_study_id>
    <nct_id>NCT03121053</nct_id>
  </id_info>
  <brief_title>Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement</brief_title>
  <acronym>PANTER</acronym>
  <official_title>Preventing Contrast Induced Nephropathy After Transcatheter Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD) and (subsequent) acute kidney injury are frequent in patients
      undergoing transcatheter aortic valve implantation (TAVI). Moreover, these patients are
      easily hypervolemic and susceptible for cardiac decompensation. Prevention of contrast
      induced nephropathy (CIN) has not yet been studied in these patients, and evidence on
      different strategies is urgently needed. The objective of this study is to evaluate the
      efficacy of 250ml 1.4% sodium bicarbonate versus hypotone saline (0.65% sodiumchloride)
      hydration prior to TAVI in patients with CKD to prevent CIN.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast induced nephropathy</measure>
    <time_frame>Day 3</time_frame>
    <description>CIN is defined as an increase in Scr &gt;0.5 mg/dL or 25% within 72 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute heart failure due to volume expansion</measure>
    <time_frame>Day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of CIN or acute heart failure</measure>
    <time_frame>Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal relative change in serum creatinine</measure>
    <time_frame>Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>Day 3</time_frame>
    <description>According to AKIN classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for dialysis</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for blood transfusions</measure>
    <time_frame>Day 3 and Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of blood transfusions</measure>
    <time_frame>Day 3 and Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery of renal function in CIN patients</measure>
    <time_frame>Day 30</time_frame>
    <description>Recovery defined as an increase in serum creatinine &lt;25% or &lt;44 Î¼mol/L (0.5 mg/dL) measured at 1 month post-TAVI compared with baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Aortic Valve Disease</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Contrast Induced Nephropathy</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>sodium bicarbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250ml 1.4% sodium bicarbonate 1 h before TAVR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypotone saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.65% sodiumchloride 1 ml/kg/h for 12 h before and 12 h after TAVR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium bicarbonate</intervention_name>
    <arm_group_label>sodium bicarbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hypotone saline</intervention_name>
    <arm_group_label>hypotone saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has provided written informed consent.

          2. Patient is undergoing TAVI.

          3. Patient has an estimated GFR &lt;60ml/min/1.73m2.

        Exclusion Criteria:

          1. Patient has end-stage kidney disease requiring dialysis.

          2. Emergent TAVI (planned before next working day).

          3. Recent exposure to radiographic contrast agents (within 2 days prior to the TAVI).

          4. Allergy to contrast agent.

          5. Planned administration of dopamine, mannitol, fenoldopam or N-acetylcysteine during
             the intended time of the study.

          6. Need for continuous hydration therapy (e.g. sepsis).

          7. Multiple myeloma.

          8. Contra-indication to sodium bicarbonate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vincent Nijenhuis, MD</last_name>
    <phone>+31 65 274 2486</phone>
    <email>v.nijenhuis@antoniusziekenhuis.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Antonius hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3435CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan van der Heyden, MD, PhD</last_name>
      <phone>+31 30 609 27 74</phone>
      <email>jvdheijden@antoniusziekenhuis.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2017</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>Jan van der Heyden</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>transcatheter aortic valve implantation</keyword>
  <keyword>transcatheter aortic valve replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

